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Abstract We analyzed dystrophin alternative splicing events in
a large number of Becker muscular dystrophy (BMD) a¡ected
individuals presenting major hot-spot deletions. Evidence is
shown that altered splicing patterns in these patients do not
directly result from the gene defect but probably derive from
modi¢cations in trans- rather than cis-acting factors. Several
potential CUG-binding protein 2 (CUG-BP2) binding sites
were found to be located in the dystrophin gene region encom-
passing exons 43^60 and CUG-BP2 transcript analysis indi-
cated that not only expression levels are increased in dystrophic
muscles but also that di¡erent CUG-BP2 isoforms are ex-
pressed. The possibility that CUG-BP2 might have a role in
dystrophin splicing regulation is discussed.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Duchenne and Becker muscular dystrophies (DMD and
BMD) are allelic disorders caused by mutations in the dystro-
phin gene, located on Xp21.2. The gene is the largest known
so far and is constituted by 79 relatively small exons [1]. The
majority of DMD and BMD patients carry deletions in the
gene (60^65% of cases) [2] and, in most cases there is a good
correlation between the severity of the disease and the e¡ect of
the deletion on the reading frame: reading frame-disrupting
mutations are usually associated with a severe DMD pheno-
type, whereas in-frame deletions determine a BMD clinical
status [3]. However exceptions to the reading frame rule are
found in about 8% of patients [4] and they are thought to be
the result of alternative splicing events that modulate the clin-
ical phenotype by editing the translational reading frame [5,6].
For both BMD and DMD, considerable variability in dis-
ease presentation is found across patients carrying the same
mutation and, in both pathologies, muscle involvement can be
associated with heart disease and/or mental retardation.
The dystrophin gene undergoes extensive alternative splic-
ing. In particular, tissue-speci¢c transcripts in brain neurons,
cardiac Purkinje ¢bers, and smooth muscle cells [7,8] arise
from alternative splicing in the 3P-region, while at least 12
splicing patterns have been described in the 5P-portion of
the gene in skeletal muscle [9]. More recently 16 di¡erent
transcripts have been shown to originate from alternative
splicing of the central gene region, some of them displaying
tissue speci¢city [10].
Full-length dystrophin transcripts encode a rod-shaped 427
kDa protein consisting of four domains: an N-terminal actin
binding domain, 24 spectrin-like repeats, a cysteine rich do-
main and an unique C-terminal domain [1]. Alternative splic-
ing events that remove one or more in-frame exons from the
spectrin-like region are thus expected to result in the produc-
tion of dystrophin molecules displaying shortened rod-do-
mains. The function of such gene products, if any, is presently
unknown as well as their potential role in the modulation of
the clinical status.
We have previously shown that at least seven alternative
splicing events involve the portion of the gene encompassing
exons 44^58 in healthy skeletal muscle [10], a region that also
represent the major hot spot for intragenic deletions. Here we
have analyzed a large number of BMD a¡ected individuals
presenting major hot-spot deletions. Our data indicate that
splicing patterns involving this gene region are altered in
BMD patients but the gene defect itself is not directly respon-
sible for splicing misregulation.
2. Material and methods
2.1. Patients
Dystrophinopatic patients were selected according to standard in-
ternational criteria and BMD subjects were classi¢ed as mild, moder-
ate or severe as previously described [11].
Dystrophin gene deletion analysis was performed using routine pro-
cedures.
Mutation analysis in the CAPN3 and DYSF genes was performed
through direct sequencing of single exons ampli¢ed from genomic
DNA. All patients reported here harbor pathological single base
pair substitutions in either the CAPN3 or the DYSF genes.
2.2. Transcript analysis
Tissue samples were derived, with informed consent of the family,
from muscle biopsies of healthy individuals and patients. Dystrophin
transcript analysis was performed as previously described [10]. One
additional reverse primer was designed in exon 56 and used together
with the exon 43 nested primer to verify the presence of transcripts
lacking exons 45^55 in healthy muscles.
For semi-quantitative analysis of CUG-binding protein 2 (BP2)
transcripts, an ABI-Tet modi¢ed forward primer (sequence:
CAAATGGCAGGCATGAATGC) located in exon 8 and a reverse
oligonucleotide (sequence: CGCTGCTCGTGGTAGAGAG) local-
ized to exon 9 were used. These two exons do not undergo alternative
splicing events in human tissues being common to all CUG-BP2 iso-
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Table 1
Subjects 1^26: BMD patients; shading indicates novel splicing events. Legend: n.d.: not determined, n.a. : not applicable; F.L.: full-length transcript.
aIn-frame transcript.
bOut-of-frame transcript.
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forms [12]. PCR reactions (22 cycles) were carried out with JumpStart
REDAccuTaq DNA Polymerase (Sigma) using annealing and exten-
sion temperatures of 60 and 68‡C, respectively. Ampli¢ed products
were run on an ABI PRISM 310 Genetic Analyzer and quanti¢ed
using the GeneScan program. CUG-BP mRNA abundance was nor-
malized to GAPDH signal. To this aim GAPDH mRNA was ampli-
¢ed using an ABI-Hex modi¢ed forward primer (sequence: GTAT-
GACAACAGCCTCAAG); sequence of the reverse oligonucleotide
was GTGATGGCATGGACTGTGG. GAPDH ampli¢cation fol-
lowed the same conditions reported for CUG-BP2 and reactions
were stopped after 20 cycles.
Transcript analysis of CUG-BP2 was performed using exon 1-spe-
ci¢c forward oligonucleotides (sequences: exon 1a, CTATGA-
GAAATGAAGAGCTGC; exon 1b, GATTTCCTCCCGGACAT-
GACG; exon 1c, CTCTGCTCGACAGCAGCACG) and a reverse
primer located in exon 2 (sequence: GAGGACGTTGATCTGGTA-
GAC). Reactions were performed with annealing and extension tem-
peratures of 58 and 68‡C, respectively.
3. Results and discussion
The dystrophin gene has been shown to undergo extensive
alternative splicing events that determine the production of a
number of transcripts, most of which still lack any functional
de¢nition. Given the potential relevance of translational frame
editing on the clinical outcome of DMD and BMD patients,
analysis of alternative splicing events in dystrophic muscles
might be relevant to both diagnostic and therapeutic pur-
poses.
We have previously shown [10] that at least seven alterna-
tive splicing events involve the portion of the dystrophin gene
encompassing exons 44^58 in healthy skeletal muscle and that
deletions involving the same exons can determine diverse
splicing behaviors in di¡erent patients or even in di¡erent
tissues of the same individual. Here we have analyzed 26
BMD patients that were selected according to deletion type
so as to minimize genetic heterogeneity. In particular, 13 and
11 patients presented a 45^47 and 45^48 exon deletion, re-
spectively, while two patients displayed loss of exon 48 alone.
Data concerning analysis of dystrophin alternative splicing
events in the region encompassing exons 43^58 are reported
in Table 1.
Transcript analysis revealed that novel alternative splicing
events are activated in BMD skeletal muscles. In particular,
skipping of exons 44^50, 45^55, 45^57 and 44^57 had never
been described in healthy muscles and we could not detect it
in three control tissues from unrelated subjects. In order to
rule out the possibility that small amounts of exon 45^55
skipped products might be present in control muscles and
that their ampli¢cation might be selected against in favor of
smaller products (i.e. transcripts lacking exons 44^56), a re-
verse primer was located in exon 56 and used instead of the
nested exon 58 primer. No product corresponding to skipping
of exons 45^55 was detectable in control muscle tissues. A
similar procedure was not necessary in the case of transcripts
lacking exons 44^50, 44^57 and 45^57 that yield very short
fragments when primer pairs are located in exons 43 and 51 or
43 and 58, respectively.
The transcript lacking exons 45^57 was the most frequently
found in patients’ muscles, being present in 14 out of 26
samples. This product was either the only alternative tran-
script detectable in BMD tissues (patients 10 and 20) or was
expressed together with other alternative gene products. Splic-
ing events did not seem to correlate with deletion type since
some patients displayed the same splicing pattern despite car-
rying di¡erent exon deletions. Moreover, as it is evident from
Table 1, patients with the same deletion displayed di¡erent
splicing behaviors with respect to the loss or preservation of
alternative transcripts expressed in healthy skeletal muscle.
The clinical status of BMD patients was also evaluated and
no splicing pattern or alternative transcript could be ascribed
to any peculiar phenotypic class.
We have previously proposed that deletion extension in
£anking introns might have some relevance with respect to
splicing patterns. To verify this hypothesis, we analyzed dele-
tion breakpoints in 14 BMD patients; sequencing of the 14
junctions has been previously reported [13]. Genomic distan-
ces of both 5P and 3P deletion ends from immediately up-
stream and downstream exons were calculated as well as de-
letion size and lengths of resulting introns deriving from the
juxtaposition of deleted intervening sequences. None of these
calculations gave any clear explanation of observed splicing
patterns. As far as exclusion of exon 45 (i.e. the presence of
transcripts skipping exons 44^50 or 44^57) is concerned, it did
not correlate with deletion extension in intron 44 or with
resulting intron lengths (Table 1). Similarly, the presence or
absence of transcripts lacking exons 45^49 did not depend
upon breakpoint location in intron 48. Overall, no evident
explanation of splicing patterns could be derived from the
analysis of breakpoint locations.
Taken together, these ¢ndings made us speculate that splic-
ing patterns might be independent from the genetic defect and
might instead be related to the patho-physiology of dystrophic
Fig. 1. URE location along the dystrophin gene. Vertical lines represent exons, dots indicate UREs.
Fig. 2. RT-PCR ampli¢cation of dystrophin transcripts arising from alternative splicing of the gene region encompassing exons 33^43. Skipped
exons are reported for each ampli¢ed product while lane headings indicate patient number. M.W.: Molecular weight marker.
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muscles. To test this hypothesis, splicing events involving
exons 44^58 were analyzed in DMD patients carrying prox-
imal deletions and in skeletal muscles from dystrophic pa-
tients with di¡erent gene defects (two patients carried muta-
tions in the calpain3 gene, one in the dysferlin gene). These
patients displayed both loss of physiological dystrophin tran-
scripts and the presence of one or more novel splicing prod-
ucts (Table 1). Interestingly, these same ¢ndings also applied
to skeletal muscle transcripts from one patient a¡ected by
myotonic dystrophy (MD). These data indicate that dystro-
phin alternative splicing patterns do not directly result from
the gene defect and implicitly suggest that modi¢cations in
trans- rather than cis-acting factors might be regarded as re-
sponsible for altered splice-site selection in dystrophic
muscles.
It has recently been reported that CUG-BP2 mRNA is
over-expressed in DMD skeletal muscles and its role in splic-
ing regulation as well as disease progression has been pro-
posed [14]. CUG-BP2 belongs to a family of highly conserved
proteins that are involved in regulation of cell-speci¢c and
developmentally regulated alternative splicing [15]. CUG-
BPs function is altered in MD, resulting in aberrant mRNA
processing of several genes [16,17]. CUG-BP2 binds to re-
peated elements of purine and uridine (UREs) [18], which
are located in intervening regions of CUG-BP2-regulated
mRNAs. We searched for such elements throughout the dys-
trophin gene and their distribution is reported in Fig. 1. Sev-
eral UREs were present in the gene region encompassing
exons 43^60, many of them being located close to intron^
exon boundaries. Conversely, a lower URE concentration
was evident in the portion of the gene spanning exons 7^43.
These observations, together with the identi¢cation of aber-
rant transcripts shared among dystrophinopatic patients and
the MD1 subject, led us to speculate that CUG-BP2 might
have a role in dystrophin splicing misregulation. We thus
analyzed alternative splicing events involving exons 33^43, a
region that displays a lower UREs concentration, and CUG-
BP2 expression in BMD skeletal muscle.
Transcript analysis of the gene region encompassing exons
33^43 was performed for patients 3, 4, 12, 13, 19, 21, 22, 25
(BMD), 27 (DMD), 31 (carrying a CAPN3 mutation) and 33
(MD1). Data are reported in Fig. 2 and indicate that loss of
physiological splicing patterns does occur in this region, but
generation of aberrant novel products does not.
Semi-quantitative RT-PCR reactions were then performed
to determine CUG-BP2 expression levels in dystrophic skele-
tal muscle (Fig. 3). Three healthy muscles were analyzed for
CUG-BP2 mRNA expression, providing very similar results.
As it is evident from Table 1, BMD patients displayed a var-
iable up-regulation of CUG-BP2, with some of them express-
ing mRNA amounts similar to control tissues and other pre-
senting a dramatic increase in transcript levels. Overall, 21 out
of 26 BMD patients displayed increased CUG-BP2 mRNA
expression and transcript levels did not correlate with age at
biopsy; nonetheless, we were unable to identify any clear re-
lation between CUG-BP2 expression levels and splicing pat-
terns or clinical phenotype in BMD patients. Yet our data
indicate that not only expression levels are increased in dys-
trophic muscles but also that di¡erent CUG-BP2 isoforms are
expressed. Three CUG-BP2 gene products are known to date
that di¡er predominantly in their ¢rst exons (exons 1a, 1b, 1c)
[12] ; analysis of CUG-BP2 transcripts in six BMD, one DMD
and the MD1 samples (Fig. 4) revealed that while only the
exon 1c isoform is expressed in control tissues, almost all
patients express the exon 1b isoform and some of them also
exon 1a. At present the function of CUG-BP2 ¢rst exon alter-
native usage is unknown and the possibility that it might
regulate substrate speci¢city, including dystrophin transcripts,
is intriguing.
Although the role of CUG-BP2 in dystrophin splicing reg-
ulation requires further studies, our data suggest a new role
for trans-acting factors in dystrophin pre-mRNA processing
in dystrophic muscles.
Since the ‘reading frame rule’ has been developed, all ex-
ceptions to it have been ascribed to the presence of alterna-
tively spliced transcripts, indicating the importance of pre-
mRNA editing on disease presentation in DMD/BMD pa-
tients. Coherently, novel gene therapy approaches based on
Fig. 3. CUG-BP2 transcript analysis. Patient numbers are indicated.
CTR: Control muscle tissue.
Fig. 4. CUG-BP2 isoform expression. Lane headings indicate patient
number.
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exon skipping induction have recently been proposed for the
treatment of DMD. The observations reported here might
o¡er a valuable insight into the patho-physiology of dystro-
phin splicing regulation and indicate that any such therapeutic
approach should take into account possible splicing altera-
tions taking place in pathological tissues. We consider that
understanding the molecular mechanisms underlying splicing
regulation will provide insight into novel targets for therapeu-
tic intervention in DMD/BMD.
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